House lawmakers are raising concerns over the Department of Veterans Affairs’ (VA) relationship with consulting firm McKinsey & Company, questioning the integrity of their collaboration in light of McKinsey’s concurrent advisory services to opioid manufacturers. A group of congressmen expressed their alarm in a letter to the VA, following a report by The Wall Street Journal that outlined McKinsey’s dual role of consulting for the VA on health-care strategies while also advising pharmaceutical giants like Purdue Pharma on strategies to enhance opioid sales within VA care.
This revelation has ignited fears of a significant conflict of interest, suggesting McKinsey could have exploited its advisory position with the VA to favor its pharmaceutical clients, potentially exacerbating the opioid crisis among veterans.
The opioid epidemic has had a devastating impact on the American population, including veterans who were often at the forefront of opioid prescription practices in the 2010s. During this period, the VA reported a peak in opioid prescriptions with nearly 900,000 veterans receiving such medication in 2012. The scrutiny over McKinsey’s role comes amidst efforts by the VA to significantly reduce opioid prescriptions.
Despite these efforts, recent disclosures and legal settlements involving McKinsey have prompted lawmakers to demand a thorough investigation into the consulting firm’s influence over VA policies and decisions
Expanded Coverage:
